Abstract
Improved understanding of the biology and molecular subtypes of non-small cell lung cancer have led to more biomarker-directed therapies for patients with metastatic disease. These biomarker-directed therapies and newer empirical treatment regimens have improved overall survival for patients with metastatic non-small cell lung cancer.
Keywords
MedicineCrizotinibLung cancerGefitinibPemetrexedErlotinibCarboplatinROS1Targeted therapyCancer researchOncologyAnaplastic lymphoma kinaseAfatinibCancerInternal medicineChemotherapyEpidermal growth factor receptorAdenocarcinomaCisplatin
Affiliated Institutions
Related Publications
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement. (Funded by Pfizer; ClinicalTrial...
A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer
Our aim was to evaluate the clinical effectiveness of chemotherapy treatments currently licensed in Europe and recommended by the National Institute for Health and Care Excellen...
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
None of four chemotherapy regimens offered a significant advantage over the others in the treatment of advanced non-small-cell lung cancer.
Effects of conventional therapeutic interventions on the number and function of regulatory T cells
Several lines of investigation have revealed the apparent interplay between the immune system of the host and many conventional, "standard-of-care" anticancer therapies, includi...
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) provide recommended management for patients with NSCLC, including diagnosi...
Publication Info
- Year
- 2019
- Type
- review
- Volume
- 322
- Issue
- 8
- Pages
- 764-764
- Citations
- 1045
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
1045
OpenAlex
Cite This
Kathryn C. Arbour,
Gregory J. Riely
(2019).
Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer.
JAMA
, 322
(8)
, 764-764.
https://doi.org/10.1001/jama.2019.11058
Identifiers
- DOI
- 10.1001/jama.2019.11058